Celgene and Juno Therapeutics announce collaboration for development and commercialization of immunotherapies
Clients Celgene Corporation
Jones Day is acting as tax counsel to Celgene Corporation in its global collaboration with Juno Therapeutics for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to commercialize Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates. Upon closing, Juno receives an upfront payment of approximately $150 million, and in addition Celgene purchases 9,137,672 shares of Juno's common stock at $93.00 per share.